Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Latest Information Update: 14 Jan 2026
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
Most Recent Events
- 23 Dec 2025 Planned End Date changed from 31 Dec 2026 to 31 Dec 2027.
- 23 Dec 2025 Planned primary completion date changed from 30 Nov 2025 to 30 Nov 2026.
- 09 Apr 2025 Status changed from recruiting to active, no longer recruiting.